BACKGROUND: Lymph node (LN) metastasis is an important predictor of survival for patients with non-small cell lung cancer (NSCLC). However, the prognostic significance of the extent of LN involvement among patients with N1 disease remains unknown. A study was undertaken to evaluate whether involvement of a higher number of N1 LNs is associated with worse survival independent of known prognostic factors. METHODS: Using the Surveillance, Epidemiology and End Results-Medicare database, 1682 resected patients with N1 NSCLC diagnosed between 1992 and 2005 were identified. As the number of positive LNs is confounded by the total number of LNs sampled, the cases were classified into three groups according to the ratio of positive to total number of LNs removed (LN ratio (LNR)): ≤0.15, 0.16-0.5 and >0.5. Lung cancer-specific and overall survival was compared between these groups using Kaplan-Meier curves. Stratified and Cox regression analyses were used to evaluate the relationship between the LNR and survival after adjusting for potential confounders. RESULTS: Lung cancer-specific and overall survival was lower among patients with a high LNR (p<0.0001 for both comparisons). Median lung cancer-specific survival was 47 months, 37 months and 21 months for patients in the ≤0.15, 0.16-0.5 and >0.5 LNR groups, respectively. In stratified and adjusted analyses, a higher LNR was also associated with worse lung cancer-specific and overall survival. CONCLUSIONS: The extent of LN involvement provides independent prognostic information in patients with N1 NSCLC. This information may be used to identify patients at high risk of recurrence who may benefit from aggressive postoperative therapy.
BACKGROUND: Lymph node (LN) metastasis is an important predictor of survival for patients with non-small cell lung cancer (NSCLC). However, the prognostic significance of the extent of LN involvement among patients with N1 disease remains unknown. A study was undertaken to evaluate whether involvement of a higher number of N1 LNs is associated with worse survival independent of known prognostic factors. METHODS: Using the Surveillance, Epidemiology and End Results-Medicare database, 1682 resected patients with N1 NSCLC diagnosed between 1992 and 2005 were identified. As the number of positive LNs is confounded by the total number of LNs sampled, the cases were classified into three groups according to the ratio of positive to total number of LNs removed (LN ratio (LNR)): ≤0.15, 0.16-0.5 and >0.5. Lung cancer-specific and overall survival was compared between these groups using Kaplan-Meier curves. Stratified and Cox regression analyses were used to evaluate the relationship between the LNR and survival after adjusting for potential confounders. RESULTS:Lung cancer-specific and overall survival was lower among patients with a high LNR (p<0.0001 for both comparisons). Median lung cancer-specific survival was 47 months, 37 months and 21 months for patients in the ≤0.15, 0.16-0.5 and >0.5 LNR groups, respectively. In stratified and adjusted analyses, a higher LNR was also associated with worse lung cancer-specific and overall survival. CONCLUSIONS: The extent of LN involvement provides independent prognostic information in patients with N1 NSCLC. This information may be used to identify patients at high risk of recurrence who may benefit from aggressive postoperative therapy.
Authors: Anil Potti; Sayan Mukherjee; Rebecca Petersen; Holly K Dressman; Andrea Bild; Jason Koontz; Robert Kratzke; Mark A Watson; Michael Kelley; Geoffrey S Ginsburg; Mike West; David H Harpole; Joseph R Nevins Journal: N Engl J Med Date: 2006-08-10 Impact factor: 91.245
Authors: Toshio Fujimoto; Stephen D Cassivi; Ping Yang; Sunni A Barnes; Francis C Nichols; Claude Deschamps; Mark S Allen; Peter C Pairolero Journal: J Thorac Cardiovasc Surg Date: 2006-07-28 Impact factor: 5.209
Authors: Suzanne K Lau; Paul C Boutros; Melania Pintilie; Fiona H Blackhall; Chang-Qi Zhu; Dan Strumpf; Michael R Johnston; Gail Darling; Shaf Keshavjee; Thomas K Waddell; Ni Liu; Davina Lau; Linda Z Penn; Frances A Shepherd; Igor Jurisica; Sandy D Der; Ming-Sound Tsao Journal: J Clin Oncol Date: 2007-12-10 Impact factor: 44.544
Authors: Juan P Wisnivesky; Ethan Halm; Marcelo Bonomi; Charles Powell; Emilia Bagiella Journal: Am J Respir Crit Care Med Date: 2009-11-05 Impact factor: 21.405
Authors: Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag Journal: Ann Epidemiol Date: 2007-05-25 Impact factor: 3.797
Authors: Chukwumere E Nwogu; Adrienne Groman; Daniel Fahey; Sai Yendamuri; Elisabeth Dexter; Todd L Demmy; Austin Miller; Mary Reid Journal: Ann Thorac Surg Date: 2012-03-20 Impact factor: 4.330
Authors: Qian Li; Ping Zhan; Dongmei Yuan; Tangfeng Lv; Alexander Sasha Krupnick; Antonio Passaro; Alessandro Brunelli; Matthew P Smeltzer; Raymond U Osarogiagbon; Yong Song Journal: Transl Lung Cancer Res Date: 2016-06
Authors: Paolo Borghetti; Fernando Barbera; Marco Lorenzo Bonù; Francesca Trevisan; Stefano Ciccarelli; Paola Vitali; Marta Maddalo; Luca Triggiani; Nadia Pasinetti; Sara Pedretti; Bartolomea Bonetti; Gianluca Pariscenti; Andrea Tironi; Alberto Caprioli; Michela Buglione; Stefano Maria Magrini Journal: Radiol Med Date: 2016-05-26 Impact factor: 3.469
Authors: Peter M Vila; Chaz L Stucken; Luc G T Morris; Marshall R Posner; Eric M Genden; Paolo Boffetta; Andrew G Sikora Journal: Eur Arch Otorhinolaryngol Date: 2013-11-05 Impact factor: 2.503